• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (159)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Oncology  • Oncology, Other  • Cardiovascular System  • Pulmonary Diseases, Other  • Renal Diseases  • Renal Diseases, Other  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Helen K. Chew, MD; Theodore Wun, MD; Danielle Harvey, PhD; Hong Zhou, PhD; Richard H. White, MD

Arch Intern Med. 2006;166:458-464.

Background:  The incidence of venous thromboembolism after diagnosis of specific cancers and the effect of thromboembolism on survival are not well defined.

Methods:  The California Cancer Registry was linked to the California Patient Discharge Data Set to determine the incidence of venous thromboembolism among cancer cases diagnosed between 1993 and 1995. The incidence and timing of thromboembolism within 1 and 2 years of cancer diagnosis and the risk factors associated with thromboembolism and death were determined.

Results:  Among 235 149 cancer cases, 3775 (1.6%) were diagnosed with venous thromboembolism within 2 years, 463 (12%) at the time cancer was diagnosed and 3312 (88%) subsequently. In risk-adjusted models, metastatic disease at the time of diagnosis was the strongest predictor of thromboembolism. Expressed as events per 100 patient-years, the highest incidence of thromboembolism occurred during the first year of follow-up among cases with metastatic-stage pancreatic (20.0), stomach (10.7), bladder (7.9), uterine (6.4), renal (6.0), and lung (5.0) cancer. Adjusting for age, race, and stage, diagnosis of thromboembolism was a significant predictor of decreased survival during the first year for all cancer types (hazard ratios, 1.6-4.2; P<.01).

Conclusions:  The incidence of venous thromboembolism varied with cancer type and was highest among patients initially diagnosed with metastatic-stage disease. The incidence rate of thromboembolism decreased over time. Diagnosis of thromboembolism during the first year of follow-up was a significant predictor of death for most cancer types and stages analyzed. For some types of cancer, the incidence of thromboembolism was sufficiently high to warrant prospective clinical trials of primary thromboprophylaxis.

Author Affiliations: Divisions of Hematology/Oncology (Drs Chew and Wun) and General Medicine (Drs Zhou and White), Department of Internal Medicine, and Department of Public Health Sciences (Dr Harvey), University of California, Davis, Sacramento; and Section of Hematology and Oncology, Veterans Affairs Northern California Health Care System, Sacramento (Dr Wun).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention and treatment of venous thromboembolism in patients with cancer
Hogg and Carrier
Therapeutic Advances in Hematology 2012;3:45-58.
ABSTRACT  

Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Kahn et al.
Chest 2012;141:e195S-e226S.
ABSTRACT | FULL TEXT  

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
Petrelli et al.
Ann Oncol 2012;0:mdr592v1-mdr592.
ABSTRACT | FULL TEXT  

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'
Mandala et al.
Ann Oncol 2011;0:mdr524v1-mdr524.
ABSTRACT | FULL TEXT  

Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer
Chavez-MacGregor et al.
Ann Oncol 2011;22:2394-2402.
ABSTRACT | FULL TEXT  

Transient Elevation of International Normalized Ratio During Cisplatin-Based Chemotherapy in Patients Who Are Taking Warfarin
Yano et al.
The Annals of Pharmacotherapy 2011;45:e55-e55.
ABSTRACT | FULL TEXT  

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
Moore et al.
JCO 2011;29:3466-3473.
ABSTRACT | FULL TEXT  

Venous Thromboembolic Disease
Streiff et al.
J Natl Compr Canc Netw 2011;9:714-777.
FULL TEXT  

Incidence of Venous Thromboembolism during Chemotherapy for Breast Cancer: Impact on Cancer Outcome
KIRWAN et al.
Anticancer Res 2011;31:2383-2388.
ABSTRACT | FULL TEXT  

Prediction of venous thromboembolism in cancer patients
Ay et al.
Blood 2010;116:5377-5382.
ABSTRACT | FULL TEXT  

Evidence-Based Mini-Review: Should All Patients with Idiopathic Venous Thromboembolic Events Be Screened Extensively for Occult Malignancy?
Rosovsky and Lee
ASH Education Book 2010;2010:150-152.
FULL TEXT  

Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma
Poruk et al.
Cancer Epidemiol. Biomarkers Prev. 2010;19:2605-2610.
ABSTRACT | FULL TEXT  

Review Article: Role of Palliative Low-Molecular-Weight Heparin for Treating Venous Thromboembolism in Patients With Advanced Cancer
Tran
AM J HOSP PALLIAT CARE 2010;27:416-419.
ABSTRACT  

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events
Caruso et al.
Blood 2010;115:5322-5328.
ABSTRACT | FULL TEXT  

Risk Factors for Venous Thromboembolism
Goldhaber
J Am Coll Cardiol 2010;56:1-7.
ABSTRACT | FULL TEXT  

Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER)
Kucher et al.
Ann Oncol 2010;21:931-935.
ABSTRACT | FULL TEXT  

Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients
Mandala et al.
Ann Oncol 2010;21:911-913.
FULL TEXT  

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
Mandala et al.
Ann Oncol 2010;21:871-876.
ABSTRACT | FULL TEXT  

Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action
Khorana et al.
JCO 2009;27:4919-4926.
ABSTRACT | FULL TEXT  

Assessing Risk of Venous Thromboembolism in the Patient With Cancer
Khorana and Connolly
JCO 2009;27:4839-4847.
ABSTRACT | FULL TEXT  

Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival
Kuderer et al.
JCO 2009;27:4902-4911.
ABSTRACT | FULL TEXT  

Cancer, Clots and Consensus: New Understanding of an Old Problem
Lyman and Khorana
JCO 2009;27:4821-4826.
FULL TEXT  

Update on acute pulmonary embolism
Sanchez et al.
Eur Respir Rev 2009;18:137-147.
FULL TEXT  

D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
Ay et al.
JCO 2009;27:4124-4129.
ABSTRACT | FULL TEXT  

Preventing venous thromboembolism in cancer patients: can we do better?
Lyman
J Oncol Pract 2009;5:165-166.
FULL TEXT  

Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations
Mandala et al.
Ann Oncol 2009;20:iv182-iv184.
FULL TEXT  

Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival
Ku et al.
Blood 2009;113:3911-3917.
ABSTRACT | FULL TEXT  

Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer
Khorana et al.
Arch Intern Med 2008;168:2377-2381.
ABSTRACT | FULL TEXT  

Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
Ashrani et al.
ASH ANNUAL MEETING ABSTRACTS 2008;112:3822-3822.
ABSTRACT  

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention
Gerber et al.
Blood 2008;112:504-510.
ABSTRACT | FULL TEXT  

Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Geerts et al.
Chest 2008;133:381S-453S.
ABSTRACT | FULL TEXT  

Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana et al.
Blood 2008;111:4902-4907.
ABSTRACT | FULL TEXT  

Use of Thromboprophylaxis in Palliative Care Patients: A Survey Among Experts in Palliative Care, Oncology, Intensive Care, and Anticoagulation
Kierner et al.
AM J HOSP PALLIAT CARE 2008;25:127-131.
ABSTRACT  

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman et al.
JCO 2007;25:5490-5505.
ABSTRACT | FULL TEXT  

The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients
Khorana
The Oncologist 2007;12:1361-1370.
ABSTRACT | FULL TEXT  

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
Mandala et al.
Ann Oncol 2007;18:1660-1665.
ABSTRACT | FULL TEXT  

Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
Chew et al.
JCO 2007;25:70-76.
ABSTRACT | FULL TEXT  

Catheter-Related Thrombosis: Risks, Diagnosis, and Management
Linenberger
J Natl Compr Canc Netw 2006;4:889-901.
ABSTRACT